MOSCA, MIRTA
MOSCA, MIRTA
Clinical Outcome of Patients with Gastric, Duodenal, or Rectal Neuroendocrine Tumors after Incomplete Endoscopic Resection
2024 Dell'Unto E.; Marasco M.; Mosca M.; Gallo C.; Esposito G.; Rinzivillo M.; Pilozzi E.; Orru F.; Campana D.; Massironi S.; Annibale B.; Panzuto F.
Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond
2023 Mosca M.; Nigro M.C.; Pagani R.; De Giglio A.; Di Federico A.
Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET)
2023 Lamberti G.; Prinzi N.; Bongiovanni A.; Torniai M.; Andrini E.; Biase D.D.; Malvi D.; Mosca M.; Berardi R.; Ibrahim T.; Pusceddu S.; Campana D.
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
2022 Metro G.; De Giglio A.; Ricciuti B.; Siringo M.; Marinelli D.; Gelibter A.; Pecci F.; Berardi R.; Cantini L.; Di Federico A.; Andrini E.; Mosca M.; Lamberti G.; Brambilla M.; Mountzios G.
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
2022 Di Federico A.; Mosca M.; Pagani R.; Carloni R.; Frega G.; De Giglio A.; Rizzo A.; Ricci D.; Tavolari S.; Di Marco M.; Palloni A.; Brandi G.
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
2022 Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De Giglio, Alessandro Rizzo, Dalia Ricci, Simona Tavolari, Mariacristina Di Marco, Andrea Palloni, Giovanni Brandi.
Non-small-cell lung cancer: how to manage RET-positive disease
2022 Andrini E.; Mosca M.; Galvani L.; Sperandi F.; Ricciuti B.; Metro G.; Lamberti G.
Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases
2021 Di Nunno Vincenzo; Nuvola Giacomo; Mosca Mirta; Maggio Ilaria; Gatto Lidia; Tosoni Alicia; Lodi Raffaele; Franceschi Enrico; Brandes Alba Ariela
Second-line treatment in advanced biliary tract cancer: Today and tomorrow
2020 Rizzo A.; Ricci A.D.; Tober N.; Nigro M.C.; Mosca M.; Palloni A.; Abbati F.; Frega G.; De Lorenzo S.; Tavolari S.; Brandi G.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Clinical Outcome of Patients with Gastric, Duodenal, or Rectal Neuroendocrine Tumors after Incomplete Endoscopic Resection | Dell'Unto E.; Marasco M.; Mosca M.; Gallo C.; Esposito G.; Rinzivillo M.; Pilozzi E.; Orru F.; Ca...mpana D.; Massironi S.; Annibale B.; Panzuto F. | 2024-01-01 | JOURNAL OF CLINICAL MEDICINE | - | 1.01 Articolo in rivista | - |
| Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond | Mosca M.; Nigro M.C.; Pagani R.; De Giglio A.; Di Federico A. | 2023-01-01 | BIOMOLECULES | - | 1.01 Articolo in rivista | biomolecules-13-01803.pdf |
| Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET) | Lamberti G.; Prinzi N.; Bongiovanni A.; Torniai M.; Andrini E.; Biase D.D.; Malvi D.; Mosca M.; B...erardi R.; Ibrahim T.; Pusceddu S.; Campana D. | 2023-01-01 | DIAGNOSTICS | - | 1.01 Articolo in rivista | diagnostics-13-01595-v3.pdf; diagnostics-13-01595-s001.zip |
| Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease | Metro G.; De Giglio A.; Ricciuti B.; Siringo M.; Marinelli D.; Gelibter A.; Pecci F.; Berardi R.;... Cantini L.; Di Federico A.; Andrini E.; Mosca M.; Lamberti G.; Brambilla M.; Mountzios G. | 2022-01-01 | DRUGS IN CONTEXT | - | 1.01 Articolo in rivista | - |
| Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes | Di Federico A.; Mosca M.; Pagani R.; Carloni R.; Frega G.; De Giglio A.; Rizzo A.; Ricci D.; Tavo...lari S.; Di Marco M.; Palloni A.; Brandi G. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | articolo 2022 Immunotherapy in Pancreatic Cancer Why Do We Keep Failing A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes.pdf |
| Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes | Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De G...iglio, Alessandro Rizzo, Dalia Ricci, Simona Tavolari, Mariacristina Di Marco, Andrea Palloni, Giovanni Brandi. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-14-02429 (1).pdf |
| Non-small-cell lung cancer: how to manage RET-positive disease | Andrini E.; Mosca M.; Galvani L.; Sperandi F.; Ricciuti B.; Metro G.; Lamberti G. | 2022-01-01 | DRUGS IN CONTEXT | - | 1.01 Articolo in rivista | - |
| Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases | Di Nunno Vincenzo; Nuvola Giacomo; Mosca Mirta; Maggio Ilaria; Gatto Lidia; Tosoni Alicia; Lodi R...affaele; Franceschi Enrico; Brandes Alba Ariela | 2021-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Second-line treatment in advanced biliary tract cancer: Today and tomorrow | Rizzo A.; Ricci A.D.; Tober N.; Nigro M.C.; Mosca M.; Palloni A.; Abbati F.; Frega G.; De Lorenzo... S.; Tavolari S.; Brandi G. | 2020-01-01 | ANTICANCER RESEARCH | - | 1.01 Articolo in rivista | - |